Introduction {#s0005}
============

The global incidence of lung cancer has been increasing rapidly in recent years [@bb0005]. The numbers of new lung cancer cases and deaths caused by lung cancer in China in 2015 were 733,300 and 610,200, respectively [@bb0010]. Therefore, lung cancer has become a serious threat to health. Approximately more than 50% of lung cancer patients cannot be treated by surgery due to advanced disease at the time of diagnosis [@bb0015], [@bb0020]. Squamous cell lung cancer accounts for 25--30% of non-small cell lung cancer (NSCLC). Although significant progress has been made in the treatment of non-squamous NSCLC, progress in advanced squamous cell lung cancer remains limited [@bb0025]. Platinum-based regimens, including third-generation chemotherapeutic agents such as paclitaxel, gemcitabine, vinorelbine, and docetaxel, are considered standard first-line treatments for advanced squamous cell lung cancer patients. The median survival of these patients is roughly 10--12 months [@bb0025], [@bb0030].

New third-generation chemotherapeutic agents combined with platinum have similar therapeutic effects. However, these chemotherapeutic agents may cause severe bone marrow suppression [@bb0030], [@bb0035], [@bb0040]. Paclitaxel is a compound with a taxane ring extracted and purified from *Taxus* bark [@bb0045]. Paclitaxel inhibits mitosis and tumor cell proliferation by binding to cell microtubules and inhibiting microtubule depolymerisation [@bb0050]. However, paclitaxel, which is difficult to dissolve in water, is typically prepared with polyoxyethylene castor oil for injection, which can induce histamine release and allergies and/or systemic muscle and joint pain [@bb0035], [@bb0040]. Liposomes are novel drug carriers that encapsulate insoluble paclitaxel in the liposome phospholipid bilayer to improve its solubility. Indeed, liposomal paclitaxel significantly increased the concentration of chemotherapeutic agents within the tumor *in vivo*, which improved the efficacy and reduced the side effects of anti-tumor drugs [@bb0055], [@bb0060]. In addition, clinical studies have shown that liposomal paclitaxel has similar efficacy and less toxicity compared with paclitaxel for the treatment of NSCLC [@bb0065], [@bb0070], [@bb0075].

Nedaplatin, a second-generation platinum complex, does not exhibit cross-resistance with traditional cisplatin or carboplatin [@bb0080]. In a previous clinical study, nedaplatin achieved a similar overall response rate (ORR) and overall survival (OS) rate as did cisplatin for the treatment of advanced NSCLC. The disease control rate (DCR) of nedaplatin combined with third-generation chemotherapeutic agents for advanced NSCLC reached 48.6--95.2% [@bb0085], [@bb0090]. Regarding squamous cell lung cancer, the combination of nedaplatin and docetaxel exhibited significantly improved efficacy and survival benefits compared with cisplatin combined with docetaxel [@bb0095].

It has been confirmed in colorectal cancer [@bb0100], castration-resistant advanced prostate cancer [@bb0105], and gastric cancer that the bi-weekly chemotherapy program is effective with minimal toxicity [@bb0110]. However, the efficacy and side effects of bi-weekly chemotherapy have not been investigated extensively in NSCLC. To our knowledge, a bi-weekly regimen of combined liposomal paclitaxel and nedaplatin has not been investigated as first-line chemotherapy for advanced NSCLC. Based on the promising results mentioned above, we designed a phase II trial to evaluate the efficacy and side effects of the bi-weekly program of liposomal paclitaxel combined with nedaplatin for the treatment of advanced squamous cell lung cancer.

Materials and Methods {#s0010}
=====================

Patients and Inclusion Criteria {#s0015}
-------------------------------

A total of 52 advanced squamous cell lung cancer patients who met the following inclusion criteria were included in the present prospective study: 1) histological or cytological diagnosis of stage IIIb--IV lung squamous cell carcinoma with measurable tumor lesions not treated with chemotherapy; 2) performance status (PS) score of 0--2 based on the Eastern Cooperative Oncology Group scoring system; 3) \>3 months of expected survival; 4) \>18 years of age; 5) absolute neutrophil count ≥1.5 × 10^9^/L, hemoglobin level ≥80 g/L, platelet count ≥75 × 10^9^/L, total bilirubin level ≤1.5× upper limit of normal (ULN), aspartic acid and alanine aminotransferase levels ≤2.5× ULN, and serum creatinine level ≤1.5× ULN; 6) no brain metastasis; and 7) newly diagnosed cases. This study was reviewed and approved by the Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University. Informed consent was obtained from all included patients. The trial was registered under the number ChiCTR-OIN-17011423.

The exclusion criteria were (1) breastfeeding and/or pregnant patients; (2) systematic diseases including acute infections, major cardiovascular disease such as myocardial infarction over the past 1 year, serious liver diseases, serious kidney diseases and metabolic disorders; (3) other malignant tumors during the last 5 years, except for malignant tumors that can be treated by radical resection, including *in situ* cervical cancer, basal or squamous cell skin cancer, breast *in situ* intraductal carcinoma and localized prostate cancer; and (4) viral diseases that may be transmitted *via* the blood or other body fluids, such as human immunodeficiency virus, hepatitis B or hepatitis C.

Chemotherapy {#s0020}
------------

The chemotherapy program consisted of two to six cycles, with each cycle lasting for 28 days. Intravenous infusion of liposomal paclitaxel (100 mg/m^2^) and nedaplatin (50 mg/m^2^) was conducted on days 1 and 15 of each cycle. Patients quit the chemotherapy program if intolerable side effects or rapid disease progression occurred. The 52 advanced squamous cell lung cancer patients completed a total of 186 chemotherapy cycles, and an average of 3.58 cycles was completed per patient.

To reduce the risk of allergic reactions to liposomal paclitaxel, all patients received intravenous infusion of dexamethasone (10 mg) and cimetidine (400 mg) and intramuscular injection of diphenhydramine (40 mg) prior to administration of liposomal paclitaxel. Conventional antiemetic therapy was conducted before and after chemotherapy. Granulocyte colony stimulating factor was used when appropriate.

Evaluation of Efficacy and Side-Effects {#s0025}
---------------------------------------

The primary objective of this clinical trial was to evaluate the response rate, progression-free survival (PFS), and toxicity of the combination chemotherapy regimen of liposomal paclitaxel and nedaplatin for advanced squamous cell lung cancer. Secondary objective was overall survival. Imaging examinations and tumor lesion measurements were performed every two cycles. A blood test, liver and kidney function evaluations, and electrocardiogram were conducted before and after each cycle to evaluate the side effects of the chemotherapy program. Efficacy was evaluated on the basis of the Response Evaluation Criteria in Solid Tumors 1.1 criteria and classified into four grades as follows: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (version 3.0) before each treatment cycle. Patients quit the chemotherapy program if the chemotherapy was delayed for \>3 weeks due to toxicity.

Dose Adjustment {#s0030}
---------------

The chemotherapy dose was adjusted when grade 3 or higher toxicity was observed. The chemotherapy dose was reduced by 20% or 40% when grade 3 or 4 toxicity occurred, respectively. Patients quit the chemotherapy program if the chemotherapy dose needed to be reduced by \>40%.

Statistical Analyses {#s0035}
--------------------

Statistical analyses were conducted using the SPSS 17.0 software package. OS, ORR, TTP, and toxicity were assessed for all patients. All patients received at least two cycles of toxicity assessment. The Kaplan--Meier method was used to analyze the survival data.

Results {#s0040}
=======

Patient Characteristics {#s0045}
-----------------------

A total of 52 patients with advanced squamous cell lung cancer hospitalized between July 2013 and June 2016 were enrolled in this prospective study. Patient characteristics are listed in [Table 1](#t0005){ref-type="table"}. The ages of the 52 patients (37 males and 15 females) ranged from 32 to 75 years. The median age was 61 years. The PS scores were 0--1 and 2 for 42 and 10 patients, respectively. Six and 46 patients were diagnosed with stage IIIb and IV advanced squamous cell lung cancer, respectively. Of the 52 patients, 44 were smokers (including ex-smokers).Table 1Patient characteristicsTable 1CharacteristicsPatient numberPercentage (%)**Total**52100**Sex** Male3771.2 Female1528.8**Age(years)** Median61N/A Range32--75N/A**ECOG performance status** 0815.4 13465.4 21019.2**Staging** IIIb611.5 IV4688.5**Smoking exposure** Smoking4484.6 Never smoking815.4[^2]

Efficacy {#s0050}
--------

All 52 patients completed more than two chemotherapy cycles. Efficacy evaluation was successfully conducted for all patients. Of the 52 patients, 20, 21, and 11 exhibited PR, SD, and PD after chemotherapy, respectively. A CR was not observed in any of the 52 patients. The total effective rate (CR + PR) and the disease control rate (CR + PR + SD) were 38.5% and 78.9%, respectively. All patients were followed up after the completion of chemotherapy. The median PFS was 8.5 months (95% confidence interval \[CI\]: 7.8--9.2) ([Figure 1](#f0005){ref-type="fig"}) and the median survival 16 months (95% CI: 14.1--17.9) ([Figure 2](#f0010){ref-type="fig"}).Figure 1Kaplan--Meier curve of progression-free survival.Figure 1Figure 2Kaplan--Meier curve of overall survival.Figure 2

Side-Effects {#s0055}
------------

Most of the side effects observed were reversible. The most common side effect was myelosuppression. Grade 3 neutropenia was noted in seven patients (13.5%), whereas no patient had grade 4 neutropenia. Grade 3 anemia was noted in four patients (7.7%), whereas no patient had grade 4 anemia. No patient had grade 2 or higher thrombocytopenia, and no grade 3 or 4 non-bone marrow toxicity was observed. Grade 1 allergic reactions induced by nedaplatin were found in two cases. Other side effects were mild and tolerable. No treatment-related death was reported ([Table 2](#t0010){ref-type="table"}).Table 2Treatment-related adverse events (n = 52)Table 2Side effectsNCI-CTCAE grade n(% of patients)1234Neutropenia16(30.8%)7(13.5%)7(13.5%)0Thrombocytopenia8(15.4%)5(9.6%)00anemia10(19.2%)6(11.5%)4(7.7%)0Nausea/vomiting15(28.8%)8(15.4%)00Allergic reactions2(3.8%)000Liver damage5(9.6%)000Renal impairment2(3.8%)000Hair loss14(26.9%)5(9.6%)00neurotoxicity11(21.2%)6(11.5%)00[^3]

Discussion {#s0060}
==========

As a novel chemotherapeutic agent, paclitaxel has become one of the most effective drugs for the treatment of advanced NSCLC. The effective rates of single-agent chemotherapy using paclitaxel and combination chemotherapy using paclitaxel and cisplatin are 21--24% and 42%, respectively [@bb0040], [@bb0050], [@bb0115], [@bb0120]. While paclitaxel has been widely used as an effective drug for the treatment of NSCLC, severe allergic reactions and peripheral nerve toxicity limit the clinical application of paclitaxel in chemotherapy [@bb0045], [@bb0050].

Liposomes are lipid spheres composed of phospholipids. As a novel drug carrier, liposomes can reduce drug toxicity, alter the dynamic properties and tissue distribution of drugs, and decrease the drug elimination rate to prolong the drug action time [@bb0055], [@bb0060]. Thus, liposomal adriamycin and liposomal cisplatin have been used clinically [@bb0125], [@bb0130]. Liposomes can significantly improve the solubility of paclitaxel in water and reduce drug toxicity, especially allergic reactions. In addition, liposomal paclitaxel exhibits sustained-release effects *in vivo* and causes minimal side effects, such as bone marrow suppression and liver toxicity [@bb0055], [@bb0060]. Moreover, liposomal paclitaxel is at least as effective as paclitaxel for advanced NSCLC [@bb0065], [@bb0070], [@bb0075]. Nedaplatin is a second-generation platinum drug that was approved in China in 2001. After nedaplatin enters cells, the bond between alcoholic oxygen and platinum on the glycolate breaks to release the platinum. Free platinum in cells binds to water to produce a number of ions that bind to DNA and inhibit DNA replication and tumor cell growth [@bb0095]. Nedaplatin has shown significant activity against advanced NSCLC (especially squamous cell lung cancer) and causes less renal and gastrointestinal toxicities than does cisplatin [@bb0085], [@bb0090], [@bb0095], [@bb0135]. Recently, another phase 3 trial has been reported that nedaplatin offers advantage over cisplatin in patients with advanced squamous cell lung cancer [@bb0140]. Therefore, a combination of liposomal paclitaxel and nedaplatin to treat advanced squamous cell lung cancer is very rational.

Liposomal paclitaxel has not been widely used in the clinic in most countries. Therefore, few studies have reported on the combination of liposomal paclitaxel and nedaplatin for the treatment of advanced NSCLC. However, the 3-week chemotherapy regimen of liposomal paclitaxel combined with nedaplatin has been widely used for the treatment of NSCLC (especially squamous cell lung cancer) in China. The reported efficiency of the 3-week chemotherapy regimen of liposomal paclitaxel plus nedaplatin for the treatment of NSCLC reached up to 40%, and the major side effect was bone marrow suppression. Based on promising results obtained from the bi-weekly chemotherapy regimens [@bb0145], [@bb0150], [@bb0155] and the minimal side effects of the 3-week chemotherapy regimen, we hypothesized that bi-weekly administration of liposomal paclitaxel and nedaplatin may be effective and better tolerated than the 3-week regimen in patients with advanced NSCLC. To test this hypothesis, we designed this prospective trial.

A multi-centre phase II trial conducted in Greece revealed that the efficacy of a bi-weekly regimen of docetaxel combined with gemcitabine for first-line treatment of advanced NSCLC was similar to those of other 3-week regimens, with high safety and tolerability. Among the 31 patients evaluated, 16 cases of PR (16/31, 55.2%) and 3 cases of SD (3/31, 10.3%) were reported. The median TTP was 3 months (range 0--12 months), with a mean OS of 10 months (range 3--31 months) [@bb0155]. In a randomized, open-label, phase 3 study, Shukuya et al. reported that first-line treatment with nedaplatin and docetaxel exhibited significantly better efficacy and survival benefits than did cisplatin combined with docetaxel in patients with squamous cell lung carcinoma [@bb0095]. The ORR was 56%, with a median PFS of 4.9 months and a median OS of 13.6 months, in the nedaplatin group. In the present study, the response rate, median PFS, and median OS of the bi-weekly chemotherapy regimen of liposomal paclitaxel combined with nedaplatin for the treatment of advanced squamous cell lung cancer were 38.5%, 8.5 months, and 16 months, respectively, which are similar to those of several currently used first-line chemotherapy programs for NSCLC. While this regimen resulted in a lower response rate, it exhibited improved survival benefits. However, we are unable to conclude whether bi-weekly liposomal paclitaxel combined with nedaplatin is indeed superior or comparable to other bi-weekly or 3-week regimens as a first-line treatment in terms of efficacy. Thus, further prospective randomized studies are warranted.

In the present study, liposomes were used as paclitaxel carriers for the treatment of advanced squamous cell lung cancer and were found to reduce the allergic reactions induced by polyoxyethylene castor oil in patients. No allergic reactions induced by liposomal paclitaxel were observed, suggesting that liposomal paclitaxel is relatively safe for lung cancer chemotherapy. No renal toxicity was observed in any patient. We also observed a low incidence of nausea and vomiting (grade 2 or 3), significantly lower than the incidences reported previously for cisplatin combination chemotherapy [@bb0055], [@bb0075], [@bb0095]. The main adverse event of this combination chemotherapy program was myelosuppression. All patients tolerated the adverse effects, including hematological toxicity. Thus, these toxicities were mild and well-tolerated.

In summary, our results suggest that the bi-weekly chemotherapy regimen of liposomal paclitaxel combined with nedaplatin is useful for the treatment of advanced squamous cell lung cancer with higher safety and clinical tolerability. Less non-hematologic and hematologic toxicities were observed in this bi-weekly chemotherapy regimen (compared with platinum-based, two-drug, 3-week regimen). Bi-weekly chemotherapy regimen of liposomal paclitaxel combined with nedaplatin could be a new first line treatment option for advanced squamous cell lung cancer patients. However, there are a number of limitations to this study, such as its small sample size, lack of a control group, and limited clinical data. Therefore, multi-centre, randomized, phase 3 studies with larger sample sizes are needed to further investigate the efficacy and side effects of bi-weekly chemotherapy using liposomal paclitaxel combined with nedaplatin compared with platinum-based, two-drug, 3-week regimen for the treatment of advanced squamous cell lung cancer.
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